Adv Ther (2017) 34:2585–2600 DOI 10.1007/s12325-017-0624-6 ORIGINAL RESEARCH Dispensing Patterns of Ranibizumab and Aﬂibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia . . . Adrian Skelly Hans-Joachim Carius Vladimir Bezlyak Fred K. Chen Received: May 3, 2017 / Published online: November 21, 2017 The Author(s) 2017. This article is an open access publication December 1, 2012, and March 31, 2015, with ABSTRACT follow-up of at least 6 months. The number of ranibizumab and aﬂibercept units dispensed Introduction: Anti-vascular endothelial growth was adjusted for baseline patient Medica- factor therapy is the standard of care for neo- tion-Based Disease Burden Index (MBDBI) vascular age-related macular degeneration scores. No difference in the number of ranibi- (nAMD). The dosage of two licensed agents, zumab versus aﬂibercept units dispensed was ranibizumab and aﬂibercept, was established concluded if the 95% conﬁdence interval (CI) through clinical trials; however, it is unclear if limits of the adjusted mean difference between either agent is administered as recommended in the study cohorts were 1.00 unit or less. routine clinical practice. Using pharmacy claims Results: Baseline patient MBDBI scores were data, we investigated if the dispensing patterns similar for the ranibizumab (N =
Advances in Therapy – Springer Journals
Published: Nov 21, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera